Current and Emerging Biologics for Ulcerative Colitis
Gut and Liver
;
: 18-27, 2015.
Article
Dans Anglais
| WPRIM
| ID: wpr-61579
ABSTRACT
Conventional medical treatment for ulcerative colitis can have limited efficacy or severe adverse reactions requiring additional treatment or colectomy. Hence, different biological agents that target specific immunological pathways are being investigated for treating ulcerative colitis. Anti-tumor necrosis factor (TNF) agents were the first biologics to be used for treating inflammatory bowel disease. For example, infliximab and adalimumab, which are anti-TNF agents, are being used for treating ulcerative colitis. Recently, golimumab, another anti-TNF agent, and vedolizumab, an anti-adhesion therapy, have been approved for ulcerative colitis by the U.S. Food and Drug Administration. In addition, new medications such as tofacitinib, a Janus kinase inhibitor, and etrolizumab, another anti-adhesion therapy, are emerging as therapeutic agents. Therefore, there is a need for further studies to select appropriate patient groups for these biologics and to improve the outcomes of ulcerative colitis treatment through appropriate medical usage.
Texte intégral:
Disponible
Indice:
WPRIM (Pacifique occidental)
Sujet Principal:
Pipéridines
/
Pyrimidines
/
Pyrroles
/
Facteurs biologiques
/
Rectocolite hémorragique
/
Molécules d'adhérence cellulaire
/
Janus kinases
/
Anticorps monoclonaux humanisés
/
Anticorps monoclonaux
Limites du sujet:
Humains
langue:
Anglais
Texte intégral:
Gut and Liver
Année:
2015
Type:
Article
Documents relatifs à ce sujet
MEDLINE
...
LILACS
LIS